This study is looking at how a medication called Tirzepatide affects the liver in people who have Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and obesity. MASLD is a common liver condition often linked to being overweight or having obesity. Tirzepatide is already used for type 2 diabetes and obesity, and it has shown promise for MASLD. Researchers will measure changes in MASLD-related markers after 12 months to see if Tirzepatide helps. You may be able to join if you are between 18 and 75 years old, have MASLD, and meet certain criteria related to your BMI, waist size, or blood sugar levels. The current recruitment status is unclear.

Study design

This is an interventional study with a planned enrollment of 8 participants. The study is investigating the effects of Tirzepatide.

What's involved

You would take Tirzepatide for 12 months. You would have clinic visits every 3 months, blood draws at baseline, 6, and 12 months, and liver ultrasounds at baseline and 12 months.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at 12 months, which is the duration of the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.